Allon Therapeutics

Contact
allontherapeutics.com
+16047360634

Allon Therapeutics Inc.

506–1168 Hamilton Street
V6B 2S2 Vancouver
Canada
+16047360634
allontherapeutics.com
Contact
Profile News
Contact

About Allon Therapeutics

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. In Q1 2008, Allon’s drug AL-108 demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease. Allon has Phase II human efficacy programs pursuing three large underserved markets: Alzheimer's disease, stroke and schizophrenia-related cognitive impairment. The Company is based in Vancouver.

Read more about Allon Therapeutics
Facts about Allon Therapeutics
  • Focus : Manufacturer
  • Industry : Pharma

News about Allon Therapeutics

Allon Therapeutics

07-Dec-2012 | research and development

The United States, New Zealand & Mexico Issue Patent for New Allon Platform

Allon Therapeutics Inc. announced that the United States, New Zealand and Mexican patent authorities have each issued composition of matter patents for a ...

Read news
Allon Therapeutics

30-Mar-2012 | research and development

Allon granted U.S. patent for neurotoxicity caused by anti-cancer drugs

Allon Therapeutics Inc. announced that it has been granted a U.S. patent that covers the use of the Company’s neuroprotective technology platform in the ...

Read news
Allon Therapeutics

14-Mar-2012 | research and development

Allon advances Parkinson’s disease program

Allon Therapeutics Inc. announced the completion of its first phase of work in a preclinical Parkinson’s disease (PD) model and advancement into the second ...

Read news
Allon Therapeutics

07-Mar-2012 | research and development

Allon broadens intellectual property with new patent

Allon Therapeutics Inc. announced that it has been granted a patent relating to the use of Allon’s drug candidates, including lead drug candidate ...

Read news
Allon Therapeutics

05-Dec-2011 | research and development

Allon’s intellectual property portfolio strengthened with additional U.S. patent

Allon Therapeutics Inc. announced that it has been granted a United States patent covering the use of Allon’s drug candidates, including its lead product ...

Read news
Allon Therapeutics

04-Oct-2011 | research and development

Allon granted important U.S. patent for preclinical compound AL-408

Allon Therapeutics Inc. announced that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP ( ...

Read news
Allon Therapeutics

08-Aug-2011 | research and development

Allon granted U.S. patent for davunetide as a treatment for schizophrenia

Allon Therapeutics Inc. announced that an important United States patent has been issued covering the method of use for the company’s lead product ...

Read news
Allon Therapeutics

21-Jul-2011 | research and development

New human imaging data support the neuroprotective effects of Allon’s davunetide

Allon Therapeutics Inc.  announced new findings that 12 weeks of treatment with the Company’s lead product davunetide appears to prevent cortical thinning ...

Read news
Show more news about Allon Therapeutics

Here you will find Allon Therapeutics Inc.